OpenResearchAlpha

Frontiers in Immunology · 10 Nov 2026

Dendritic cell-targeting virus-like particles as mRNA carriers induce Th1-skewed humoral and cellular immunity

Fangfeng Yuan, DongSoo Yun, Sofiya Ismagilova, Jianzhu Chen

0
Citations
no database records one yet
0
Citations in 2026
so far
–
Leading author's h-index
no author has a profile yet
14
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Messenger RNA (mRNA) vaccines have emerged as a powerful vaccination platform, yet efficient and targeted delivery of mRNA to professional antigen-presenting cells (APCs) remains a major challenge. Here, we developed a dendritic cell (DC)-targeting virus-like particle (DVLP) platform for mRNA delivery by combining human immunodeficiency virus (HIV) Gag fused with the bacteriophage MS2 coat protein, which recognizes mRNA bearing MS2 stem-loop sequences and an engineered Sindbis virus glycoprotein mutant (SV-Gmt) that preferentially targets dendritic cells. African swine fever virus (ASFV) P30 was employed as a model antigen to evaluate platform performance. In vitro , SV-Gmt-pseudotyped VLPs encapsulating P30 mRNA (DVLP-P30) preferentially delivered antigen mRNA to dendritic cells compared with broad-tropic vesicular stomatitis virus G protein (VSV-G)-pseudotyped VLPs encapsulating P30 mRNA (VSV-G VLP-P30). In mice, vaccination with DVLP-P30 induced significantly higher P30-specific antibody responses than VSV-G VLP-P30. Enhanced humoral immunity was accompanied by increased frequencies of CD4 + and CD8 + effector memory T cells, indicating improved generation of antigen-specific immune memory. Notably, DC-targeted mRNA delivery promoted stronger interferon-γ responses and increased IgG2a production, consistent with a Type 1 helper T cell (Th1)-skewed immune profile. Together, these findings demonstrate that DC-targeting VLPs function as effective mRNA carriers and enhance both the magnitude and quality of vaccine-induced immunity. This work establishes a versatile platform for targeted mRNA delivery and supports further development of DVLPs for prophylactic and therapeutic vaccination.

What the data shows

  • No database records a citation yet, as is usual for a paper this new.

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (4)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (14)

What it cites, from open citation data, with Crossref's record of each.